Whalesbook
Mixed Q4 Results Mask Strong Annual Performance
Sai Life Sciences' recent quarterly results showed slower growth, with revenue up 4% and EBITDA up 11% year-on-year. This slowdown stems from the natural project transitions in its CDMO business. However, the full fiscal year 2026 was strong, with revenues rising 29% and EBITDA surging 56%. The CDMO segment, making up 65% of sales, grew 33% last year. Margins are stabilizing around 28-30%, a big jump from five years ago. Strong underlying demand for drug development and manufacturing partnerships continues, shown by higher revenue from top clients.
Ambitious Capex Plan Faces Rising Cost Pressures
Sai Life Sciences is undertaking significant capital spending. After investing ₹633 crore in FY26, it plans ₹1100-1300 crore in FY27. This will boost manufacturing capacity from 700 to 1,150 kilolitres, with new capacity coming online in FY27 and FY28. Most of this spending (70%) is for CDMO services, with the rest for discovery, AI, and advanced technology. Investments are also targeting new areas like peptides, Antibody-Drug Conjugates (ADCs), and oligonucleotides. These specialized areas, now 4% of revenue (down from 7% due to clinical campaign cycles), are expected to grow significantly. However, the company faces near-term challenges from higher input and logistics costs, potentially worsened by geopolitical tensions. This could delay passing costs on, affecting margins.
Valuation Concerns and Execution Risks
Analysts point out that Sai Life Sciences is trading at a premium valuation. The stock's current EV/EBITDA multiple for FY28 is about 27 times, which needs careful review given the recent quarterly performance and potential cost pressures. This multiple is high compared to some diversified Indian drug companies, though competitive for specialized CDMOs like Syngene and Divi's Labs. The stock's 45% rise over the past year, along with the Q4 results, led some analysts to downgrade its rating to Equal-Weight, signaling a more cautious near-term view. Historically, periods of project lumpiness or slower quarterly growth have often led to temporary stock price drops for Sai Life Sciences. Recovery has typically depended on consistent annual performance and clear future guidance. While the company manages debt well, the large upcoming capital expenditure could strain near-term free cash flow if revenue growth doesn't keep pace. Focusing on complex chemistry and new modalities is promising long-term but involves longer development times and higher R&D risks than established CDMO services. Global instability also remains a risk to supply chain reliability and raw material sourcing, potentially affecting costs and project delivery.
Outlook: Long-Term Ambitions Meet Short-Term Challenges
Management still aims for long-term revenue growth of 15% to 20% annually, targeting EBITDA margins of 28% to 30% over three years. The second half of fiscal year 2027 is expected to be stronger as new capacities and investments start paying off. The company targets an asset turnover ratio between 1.2x and 1.4x, though fluctuations are expected during the heavy investment phase. The steady demand for outsourced drug development and manufacturing services provides a solid market background. However, investors will closely monitor how Sai Life Sciences handles project transitions, manages rising costs, and justifies its high valuation as new facilities ramp up. Current analyst price targets suggest limited immediate upside, reflecting a balanced view of growth prospects against the current stock price.